专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明公开

EP0210545A3 Phosphorous containing enzyme inhibitors 失效
标题翻译：含有PHOSPHOROUS的酶抑制剂
公开(公告)号：EP0210545A3
公开(公告)日：1988-07-20
申请号：EP86109764
申请日：1986-07-16
申请人： MERCK & CO. INC.
发明人： Patchett, Arthur A. , Greenlee, William J. , Parsons, William H.
IPC分类号： C07F09/30 , C07F09/32 , C07F09/65 , A61K31/66
CPC分类号： C07F9/65067 , A61K38/00 , C07F9/301 , C07F9/3211 , C07F9/5721 , C07K5/06191
摘要： Dipeptides and amino acids of the formula A-E-G are disclosed wherein A is, e.g., hydrogen, or a- , R b CO or R b SO 2 - where R a and R b are e.g., alkyl, cycloalkyl, or aryl;
wherein
R' is, e.g., alkyl; n is 0, 1; R 2 is, e.g., hydrogen or alkyl; R 3 is OH, NH 2 , , ,
are e.g., alkyl; R 4 is, e.g., hydrogen or alkyl R 6 is H or methyl; R 7 is, e.g., hydrogen or alkyl; R 8 is, e.g., hydrogen, methyl or cycloalkyl such that when R 8 is cycloalkyl, R 6 and R 7 are hydrogen; R 9 is, e.g., hydroxy. The compounds have enzyme inhibitor activity e.g., renin inhibition angiotensin converting enzyme inhibition. BACKGROUND OF THE INVENTION The present invention is concerned with novel compounds (substituted amino acids and dipeptides) which inhibit renin and in some instances also inhibit angiotensin converting enzyme (ACE). The present invention is also concerned with pharmaceutical compositions containing the novel compounds of the present invention as active ingredients, with thier use for treating renin and/or ACE associated conditions, with diagnostic methods which utilize these compounds, and with processes for their preparation. Small peptide inhibitors of renin have been reported by Kokubu et al. (Biochem. Biophys. Res. Communs, 118, 929 (1984)) and by Fehrentz et al. (Febs. Letts., 167, 273 (1984)), who described peptide aldehyde inhibitors. R. Matsuda et al. in European Patent Application 128,762 (Sankyo Co., Ltd., 1984) also disclose tripeptide aldehydes as renin inhibitors. Some of the compounds disclosed in the present invention also inhibit angiotensin-converting enzyme. Peptides containing aminophosphonic acids as the carboxyl-terminal components, which are inhibitors of A.C.E. have previously been reported by Y. Kido et al., in J. Antibiot. (Tokyo), 37, 965-9 (1984) and in Japanese Patent J59187-790-A (Kyowa Hakko Kogyo KK) (1984). Also, phosphinylalkanoyl substituted proline analogs which inhibit A.C.E. have previously been described by E. Petrillo et al., U. S. Patents No 4,168,267; 4,337,201 (E. R. Squibb and Sons, 1979, 1982). Compounds of no more than two amino acids or the equivalent, which incorporate phosphorous-containing elements as the carboxyl-terminal or next-to carboxyl-terminal component have been discovered. They are potent renin inhibitors and may be orally acive. SUMMARY OF THE INVENTION Compounds which 1) include dipeptides and substituted amino acids and 2) contain phosphorous having renin inhibitory activity and which may be orally active. The present invention comprises compounds of the following formula: A-E-G (I) wherein:
A is hydrogen, or R a -, R b CO or R b SO 2 - where R a and R b are alkyl, cycloalkyl, aryl, heterocyclic, heterocyclic alkyl, heterocyclic aryl, aryloxy alkyl, heterocyclic aryloxy alkyl, aryl alkyl, heterocyclic aryl alkyl, heterocyclic oxyalkyl, and R a and R b may be substituted with up to three members selected from amino, carboxy, alkoxy carbonyl, hydroxy, alkyl, halo and alkoxy groups. E is
G is -R 3 or is
wherein
R 1 is alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl alkyl, heterocyclic, heterocyclic alkyl, heterocyclic aryl alkyl, each of which may be substituted with up to three members selected from alkyl, halo, amino and alkoxy groups. n is 0, 1. R 2 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl, aryl alkyl, heterocyclic, heterocyclic alkyl, each of which may be substituted with up to three members selected from alkyl, hydroxy, halo, amino, alkylamino, dialkylamino, and alkoxy groups. R3 is OH, NH 2 , , , where , , and are separately alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkyl alkyl, aryl, aryl alkyl, heterocyclic, heterocyclic alkyl, each of which may be substituted with up to three groups selected from amino, alkylamino, dialkyl amino, trialkyl ammonium, hydroxy, alkoxy, aryloxy, aryl alkoxyl, or halo; R 3 may also be -CO-V- wherein is alkyl or aryl; and are hydrogen or alkyl; and V is -O- or -NH-. R 4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkyl, each of which may be substituted with up to three members selected from amino, alkylamino, dialkylamino, trialkyl ammonium, hydroxy, alkoxy, halo or alkyl groups; or -CO 4 V- wherein is alkyl or aryl; and are hydrogen or alkyl; and V is -O- or -NH-. R 6 is H or methyl. R 7 is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl cycloalkenyl, aryl, cycloalkyl alkyl, aryl alkyl, heterocyclic, heterocyclic alkyl, aryloxy alkyl, heterocyclic oxy alkyl, heterocyclic oxy, each of which may be substituted with up to three groups selected from amino, alkyl amino, dialkyl amino, trialkyl ammonium, hydroxy, alkoxy, carboxy, alkoxycarbonyl, alkylthio, arylthio, thiol, guanidino, carboxamido and alkanoylamino, and when taken together with NR 8 may be a cyclic amino acid of the formula:
where is hydrogen, phenyl, hydroxyphenyl; X is -S- or -CH 2 - or -CH- ; m is 1 or 2; and is cyclohexyl, phenylthio; W and Z are single bonds or -CH 2 -, and R 3 is as defined above. R 8 is hydrogen, methyl and cycloalkyl (including cyclopentyl and indanyl) such that when R 8 is cycloalkyl, R 6 and R 7 are hydrogen. R 9 is hydroxy, , -NH 2 , , , where , and are as defined above such that when A is absent, R 9 can be
where R 3 , 1 R 6 and R 7 are as defined above. In the above definitions, the terms alkyl, alk, alkenyl, and alkynyl include hydrocarbon groups having up to 8 carbon atoms which groups may be straight chain or branched chain. Preferred alkyl or alk groups have 1-4 carbon atoms. Preferred alkenyl and alkynyl groups have 3 to 6 carbon atoms. The term halo means fluoro, chloro, bromo and iodo. The aryl substituent is a hydrocarbon having 6-12 carbon atoms exemplified by phenyl, naphthyl, biphenyl and cycloalkyl-fused derivatives thereof such as indanyl and tetralinyl. The heterocyclic substituents recited above represents any 5- or 6-membered ring containing from one to three heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur wherein the nitrogen and sulfur heteroatoms may optionally be quaternized, and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring. Heterocyclic substituents in which nitrogen is the heteroatom are preferred; and of these, those containing a single nitrogen atom are preferred. Fully saturated and fully unsaturated heterocyclic substituents are also preferred. Thus, piperidine is a preferred saturated heterocyclic substituent. Other preferred heterocyclic substituents are pyrrolidinyl, imidazolidinyl, morpholinyl, tetrahydrofuranyl thienyl, pyrimidinyl, imidazolyl, indolyl, quinolinyl, isoquinolinyl and benzothieny groups and the like. Cycloalkyl and cycloalkenyl groups contain 3 to 12 carbon atoms and may be bridged. They are exemplified by cyclopropyl, cyclopentyl, cyclohexyl, cyclohexenyl, nobornenyl, adamantyl, bicyclo[3.3.0]-octanyl and perhydronaphthyl groups and the like. Preferred A units include benzyloxycarbonyl, t-butoxycarbonyl, 1-naphthyloxyacetyl, and 1-naphthyl- acetyl. Preferred E units include those with the following formulae:
Preferred G substituents include -OH, -OEt, -NH 2 . The compounds disclosed have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers. All isomeric forms are included in the present compounds as appropriate. The stereocenters present in the E unit of the peptides of formula I are in general of the chirality which corresponds to the naturally-occurring (L) amino acids. Thus, for example, the unit E of the formula below possesses the stereochemistry shown in the preferred form:
The following are illustrative examples of peptides of the present invention:
1. (N-carbobenzoxy-l-amino-2-cyclohexylethyl) 2-carboxy-4-methylpentylphosphinic acid 2. (N-carbobenzoxy-l-amino-2-cyclohexylethyl) 2-carboxy-3-methylbutylphosphinic acid 3. (N-t-butoxycarbonyl-1-amino-2-cyclohexylethyl) 2-carboxy-3-methylbutylphosphinic acid 4. (N-carbobenzoxy-l-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinic acid 5. (N-carbobenzoxy-1-amino-2-cyclohexylethyl) 2-carboxamido-4-methylpentylphosphinic acid 6. (N-t-butoxycarbonyl-1-amino-2-cyclohexylethyl) 2-(N-benzyl)carboxamido-3-methylbutylphosphinic acid 7. [N-(2-phenyl)ethyl-1-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentylphosphinic acid 8. [N-(N-benzyl)carboxamidomethyl-l-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid 9. [N-(1-carboethoxy-2-phenylethyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid 10. (N-carbobenzoxy-1-amino-2-cyclohexylethyl)carbo- methoxymethylphosphinic acid 11. (N-carbobenzoxy-l-amino-2-cyclohexylethyl)carboxy- methylphosphinic acid 12. (N-carbobenzoxy-l-amino-2-cyclohexylethyl) carbox- amidomethylphosphinic acid 13. (N-carbobenzoxy-l-amino-2-cyclohexylethyl) 2-carboxy-3-cyclohexylpropylphosphinic acid 14. [N-(3-phenyl)propionyl-l-amino-2-cyclohexylethyl] 2-carboxy-4-methylpentylphosphinic acid 15. (N-phenoxyacetyl-l-amino-2-cyclohexylethyl) 2-carboxy-3-methylbutylphosphinic acid 16. [N-(4-amino)butanoyl-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid 17. (N-naphthyloxyacetyl)-1-amino-2-cyclohexylethyl) 2-carboxy-3-methylbutylphosphinic acid 18. Methyl (N-carbobenzoxy-l-amino-2-cyclohexylethyl) 2-carboxy-4-methylpentylphosphinate 19. Methyl (N-carbobenzoxy-l-amino-2-cyclohexylethyl)-carbomethoxymethylphosphinate 20. Ethyl [N-(3-phenyl)propionyl-l-amino-2-cyclohexylethyl] 2-carbomethoxy-3-methylbutylphosphinate 21. [N-(1-carboethoxy-5-aminopentyl)-1-amino-2-cyclohexylethyl] 2-carboxy-3-methylbutylphosphinic acid 22. [N-(1-carbobenzoxy-5-aminopentyl)-1-amino-2-cyclohexylethyl] 2-carboethoxy-3-methylbutylphosphinic acid 23. [N-carbobenzoxy-l-amino-2-cyclohexylethyl] 2-(N-(m-aminomethyl)benzyl)carboxamido-3-methyl- butylphosphinic acid Another group of illustrative compounds are:
24. (N-CBZ-1-amino-2-cyclohexylethyl) 2-carboxy-4-methylpentylphosphinic acid 25. (N-CBZ-1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinic acid 26. Methyl (N-CBZ-1-amino-2-cyclohexylethyl) 2-carbo- methoxy-4-methylpentylphosphinate 27. Methyl (N-BOC-1-amino-2-cyclohexylethyl) 2-carbo- methoxy-4-methylpentylphosphinate 28. (1-Amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinic acid hydrobromide 29. Methyl (1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinate hydrobromide 30. Trimethylacetoxymethyl (N-CBZ-1-amino-2-cyclohexylethyl) 2-carbomethoxy-4-methylpentylphosphinate 31. Methyl (N-BOC-1-amino-2-cyclohexylethyl) 2-carbo- methoxy-4-methyl-(E)-2-pentenylphosphinate 32. Methyl (N-BOC-l-amino-2-cyclohexylethyl) 2-carbo- methoxy-4-methyl-(Z)-2-pentenylphosphinate 33. (N-BOC-1-Amino-2-cyclohexylethyl) 2-carboxy-4-methyl-(E)-2-pentenylphosphinic acid 34. (N-BOC-l-Amino-2-cyclohexylethyl) 2-carboxy-4-methyl-(Z)-2-pentenylphosphinic acid 35. Methyl (N-CBZ-l-amino-2-cyclohexylethyl) 2-carbo- methoxy-3-cyclohexylphosphinate 36. Methyl (N-CBZ-1-amino-2-cyclohexylethyl) carbomethoxymethylphosphinate 37. (1-Amino-2-cyclohexylethyl) carbomethoxymethyl- phosphinic acid 38. Methyl (1-amino-2-cyclohexylethyl)carbomethoxymethylphosphinate hydrochloride 39. Methyl (N-CBZ-1-amino-3-methylbutyl)carbomethoxymethylphosphinate 40. Methyl (N-CBZ-l-amino-2-phenylethyl) 2-carbo- methoxy-3-phenylpropylphosphinate 41. (1-Amino-2-phenylethyl) 2-carbomethoxy-3-phenyl- propylphosphinate The Formula I compounds include many which bar acidic and/or basic groups. Pharmaceutically acceptable salts of these formula I compounds are also included. Among useful the acid addition salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, and undecanoate. Salts of the bases include ammonium salts, alkali metal salts such as sodium and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Conventional processes are used to prepare the pharmaceutically acceptable salts. The present invention is also directed to combinations of the novel renin-inhibitory compounds of Formula I with one or more antihypertensive agents selected from the group consisting of diuretics, a and/or B-adrenergic blocking agents, CNS-acting antihypertensive agents, adrenergic neuron blocking agents, vasodilators, angiotensin I converting enzyme inhibitors, calcium channel blockers and other antihypertensive agents. For example, the compounds of this invention can be given in combination with such compounds or salt or other derivative forms thereof as:
Diuretics: acetazolamide; amiloride; bendroflumethiazide; benzthiazide; bumetanide; chlorothiazide; chlorthalidone; cyclothiazide; ethacrynic acid; furosemide; hydrochlorothiazide; hydroflumethiazide; indacrinone (racemic mixture, or as either the (+) or (-) enantiomer alone, or a manipulated ratio, e.g., 9:1 of said enantiomers, respectively); metolazone; methyclothiazide; muzolimine; polythiazide; quinethazone; sodium ethacrynate; sodium nitroprusside; spironolactone; ticrynafen; triamterene; trichlormethiazide; a-Adrenergic Blocking Agents: dibenamine; phentolamine; phenoxybenzamine; prazosin; tolazoline; B-Adrenergic Blocking Agents: atenolol; metoprolol; nadolol; propranolol; timolol; ((±)-2-[3-(tert-butylamino)-2-hydroxypropoxy]-2-furan- anilide) (ancarolol); (2-acetyl-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran HC1) (befunolol); ((+)-1-(isopropylamino)-3-(p-(2-cyclopropylmethoxyethyl)-phenoxy)-2-propranol HC1) (betaxolol); (1-[(3,4-dimethoxyphenethyl)amino]-3-(m-tolyloxy)-2-propanol HC1) (bevantolol); (((±)-1-(4-((2-isopropoxyethoxy)methyl)phenoxy)-3-iso- propylamino-2-propanol)fumarate) (bisoprolol); (4-(2-hydroxy-3-[4-(phenoxymethyl)-piperidino]-propoxy)-indole); (carbazolyl-4-oxy-5,2-(2-methoxyphenoxy)-ethylamino-2-propanol); (1-((1,1-dimethylethyl)amino)-3-((2-methyl-1H-indol-4-yl)oxy)-2-propanol benzoate) (bopindolol); (1-(2-exobicyclo[2.2.1]-hept-2-ylphenoxy)-3-[(1-methylethyl)-amino]-2-propanol HC1) (bornaprolol); (o-[2-hydroxy-3-[(2-indol-3-yl-1,1-dimethylethyl)-amino]propoxy]benzonitrile HC1) (bucindolol); (a-[(tert.butylamino)methyl]-7-ethyl-2-benzofuranmethanol) (bufuralol); (3-[3-acetyl-4-[3-(tert.butylamino)-2-hydroxypropyl]-phenyl]-1,1-diethylurea HC1) (celiprolol); ((+)-2-[2-13-[(1,1-dimethylethyl)amino]-2-hydroxy- propoxy]phenoxy]-N-methylacetamide HC1) (cetamolol); (2-benzimidazolyl-phenyl(2-isopropylaminopropanol)); ((+)-3'-acetyl-4'-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide HC1) (diacetolol); (methyl-4-[2-hydroxy-3-[(l-methylethyl)aminopropoxy]]-benzenepropanoate HCl) (esmolol); (erythro-DL-1-(7-methylindan-4-yloxy)-3-isopropylaminobutan-2-ol); (1-(tert.butylamino)-3-[O-(2-propynyloxy)phenoxy]-2-propanol (pargolol); (1-(tert.butylamino)-3-[o-(6-hydrazino-3-pyridazinyl)-phenoxy]-2-propanol diHCl) (prizidilol); ((-)-2-hydroxy-5-[(R)-1-hydroxy-2-[(R)-(1-methyl-3-phenylpropyl)amino]ethyl]benzamide); (4-hydroxy-9-[2-hydroxy-3-(isopropylamino)-propoxy]-7-methyl-5H-furo[3,2-g][1]-benzopyran-5-one) (iprocrolol); ((-)-5-(tert.butylamino)-2-hydroxypropoxy]-3,4-dihydro-1-(2H)-naphthalenone HC1) (levobunolol); (4-(2-hydroxy-3-isopropylamino-propoxy)-1,2-benziso- thiazole HC1); (4-[3-(tert.butylamino)-2-hydroxypropoxy]-N-methylisocarbostyril HC1); ((+)-N-2-[4-(2-hydroxy-3-isopropyl aminopropoxy)-phenyl]ethyl-N'-isopropylurea) (pafenolol); (3-[[(2-trifluoroacetamido)ethyl]amino]-1-phenoxy- propan-2-ol); (N-(3-(o-chlorophenoxy)-2-hydroxypropyl)-N'-(4'-chloro-2,3-dihydro-3-oxo-5-pyridazinyl)ethylenediamine); ((±)-N-[3-acetyl-4-[2-hydroxy-3-[(1-methylethyl)amino]-propoxy]phenyl]butanamide) (acebutolol); ((+)-4'-[3-(tert-butylamino)-2-hydroxypropoxy]spiro-[cyclohexane-1,2'-indan]-1'-one) (spirendolol); (7-[3-[[2-hydroxy-3-[(2-methylindol-4-yl)oxy]propyl]-amino]butyl]thiophylline) (teoprolol); ((±)-1-tert.butylamino-3-(thiochroman-8-yloxy)-2-propanol) (tertatolol); ((±)-1-tert.butylamino-3-(2,3-xylyloxy)-2-propanol HC1) (xibenolol); (8-[3-(tert.butylamino)-2-hydroxypropoxy]-5-methyl- coumarin) (bucumolol); (2-(3-(tert.butylamino)-2-hydroxy-propoxy)benzonitrile HC1) (bunitrolol); ((+)-2'-[3-(tert-butylamino)-2-hydroxypropoxy-5'-fluorobutyrophenone) (butofilolol); (1-(carbazol-4-yloxy)-3-(isopropylamino)-2-propanol) (carazolol); (5-(3-tert.butylamino-2-hydroxy)propoxy-3,4-dihydro- carbostyril HC1) (carteolol); (1-(tert.butylamino)-3-(2,5-dichlorophenoxy)-2-propanol) (cloranolol); (1-(inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol HC1) (indenolol); (1-isopropylamino-3-[(2-methylindol-4-yl)oxy]-2-propanol) (mepindolol); (l-(4-acetoxy-2,3,5-trimethylphenoxy)-3-isopropylaminopropan-2-ol) (metipranolol); (1-(isopropylamino)-3-(o-methoxyphenoxy)-3-[(1-methylethyl)amino]-2-propanol) (moprolol); ((1-tert.butylamino)-3-[(5,6,7,8-tetrahydro-cis-6,7-dihydroxy-l-naphthyl)oxy]-2-propanol) (nadolol); ((S)-1-(2-cyclopentylphenoxy)-3-[(1,1-dimethylethyl)-amino]-2-propanol sulfate (2:1)) (penbutolol); (4'-[1-hydroxy-2-(amino)ethyl]methanesulfonanilide) (sotalol); (2-methyl-3-[4-(2-hydroxy-3-tert.butylaminopropoxy)-phenyl]-7-methoxy-isoquinolin-1-(2H)-one); (1-(4-(2-(4-fluorophenyloxy)ethoxy)phenoxy)-3-iso- propylamino-2-propanol HC1); ((-)-p-[3-[(3,4-dimethoxyphenethyl)amino]-2-hydroxy- propoxy]-β-methylcinnamonitrile) (pacrinolol); ((+)-2-(3'-tert.butylamino-2'-hydroxypropylthio)-4-(5'-carbamoyl-2'-thienyl)thiazole HC1) (arotinolol); ((±)-1-[p-[2-(cyclopropylmethoxy)ethoxy]phenoxy]-3-(isopropylamino)-2-propanol) (cicloprolol); ((±)-1-[(3-chloro-2-methylindol-4-yl)oxy]-3-[(2-phenoxyethyl)amino]-2-propanol) (indopanolol); ((±)-6-[[2-[[3-(p-butoxyphenoxy)-2-hydroxypropyl]-amino]ethyl]amino]-1,3-dimethyluracil) (pirepolol); (4-(cyclohexylamino)-l-(l-naphtholenyloxy)-2-butanol); (1-phenyl-3-[2-[3-(2-cyanophenoxy)-2-hydroxypropyl]-aminoethyl]hydantoin HCl); (3,4-dihydro-8-(2-hydroxy-3-isopropylaminopropoxy)-3-nitroxy-2H-1-benzopyran) (nipradolol); a and B-Adrenergic Blocking Agents:
((±)-1-tert-butylamino)-3-[o-[2-(3-methyl-5-isoxazolyl)vinyl]phenoxy]-2-propanol) (isoxaprolol); (1-isopropylamino-3-(4-(2-nitroxyethoxy)phenoxy)-2-propanol HCl); (4-hydroxy-α-[[3-(4-methoxyphenyl)-1-methylpropyl]-aminomethyl]-3-(methylsulfinyl)-benzmethanol HC1) (sulfinalol); (5-[1-hydroxy-2-[[2-(o-methoxyphenoxy)ethyl]amino]-ethyl]-2-methylbenzenesulfonamide HC1); (5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-salicylamide HC1) (labetalol); (1-((3-chloro-2-methyl-1H-inaol-4-yl)oxy)-3-((2-phenoxyethyl)amino)-2-propanol-hydrogenmalonate) (ifendolol); (4-(2-hydroxy-3-[(1-methyl-3-phenylpropyl)amino]-propoxy)benzeneacetamide); (1-[3-[[3-(1-naphthoxy)-2-hydroxypropyl]-amino]-3,3-dimethyl-propyl]-2-benzimidazolinone); (3-(l-(2-hydroxy-2-(4-chlorophenylethyl)-4-piperidyl)-3,4-dihydroxy)quinoxolin-2(lH)-one); CNS-Acting Agents: clonidine; methyldopa; Adrenergic Neuron Blocking Agents: guanethidine; reserpine and other rauwolfia alkaloids such as rescinnamine; Vasodilators: diazoxide; hydralazine; minoxidil; Angiotensin I Converting Enzyme Inhibitors:
1-(3-mercapto-2-methyl-1-oxopropyl)-L-proline (captopril); (1-(4-ethoxycarbonyl-2,4(R,R)-dimethylbutanoyl)-indoline-2(S)-carboxylic acid); (2-[2-[[1-(ethoxycarbonyl)-3-phenyl-propyl]amino]-1- oxopropyl]-1,2,3,4-tetrahydro-3-isoquinoline carboxylic acid); ((S)-1-[2-[[1-(ethaxycarbonyl)-3-phenylpropyl]amino]-1- oxopropyl]octahydro-lH-indole-2-carboxylic acid HCl); (N-cyclopentyl-N-(3-(2,2-dimethyl-l-oxopropyl)thiol-2-methyl-l-oxopropyl)glycine) (pivalopril); ((2R,4R)-2-(2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thiazolidinecarboxylic acid); (1-(N-[1(S)-ethoxycarbonyl-3-phenylpropyl]-(S)-alanyl)-cis,syn-octahydroindol-2(S)-carboxylic acid HC1); ((-)-(S)-1-[(S)-3-mercapto-2-methyl-1-oxopropyl]-indoline-2-carboxylic acid); ([1(S),4S]-1-[3-(benzoylthio)-2-methyl-1-oxopropyl]-4-phenylthio-L-proline; (3-([1-ethoxycarbonyl-3-phenyl-(1S)-propyl]amino)-2,3,4,5-tetrahydro-2-oxo-l-(3S)-benzazepine-l-acetic acid HC1); (N-(2-benzyl-3-mercaptopropanoyl)-S-ethyl-L-cysteine) and the S-methyl analogue; (N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-L-proline maleate) (enalapril); N-[1-(S)-carboxy-3-phenylpropyl]-L-alanyl-1-proline; N 2 -[1-(S)-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lysinopril); 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl-(1S,3S,5S)-2-azabicyclo[3.3.0]actane-3-carboxylic acid; [1(S),4S]-1-(3-mercapto-2-methyl-1-oxoprapyl)-4-phenylthio-L-proline S-benzoyl calcium salt (zofenopril); [1-(+/-)4S]-4-cyclohexyl-1-[[2-methyl-1-[1-(1-(oxy- propoxy)propoxy](4-phenylbutyl)phosphinyl]acetyl]-L-proline sodium salt (fosfopril). Calcium Channel Blockers: nifedepine; nitrendipine, verapamil; diltiazam. Other Antihypertensive Agents: aminophylline; cryptenamine acetates and tannates; deserpidine; meremethoxylline procaine; pargyline; trimethaphan camsylate;
and the like, as well as admixtures and combinations thereof. Typically, the individual daily dosages for these combinations can range from about one-fifth of the minimally recommended clinical dosages to the maximum recommended levels for the entities when they are given singly. Coadministration is most readily accomplished by combining the active ingredients into a suitable unit dosage form containing the proper dosages of each. Other methods of coadministration are, of course, possible. The novel compounds of the present invention possess an excellent degree of activity in treating hypertension and congestive heart failure. For these purposes the compounds of the present invention may be administered orally, parenterally, by inhalation spray, or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the tr atment of warm- blooded animals such as mice, rats, horses, dogs, cats, etc., the compounds of the invention are effective in the treatment of humans. The pharmaceutical compositions may be in the form of a sterile injectable preparation, for example as a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. The peptides of this invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols. Dosage levels of the order of 0.1 to 4.0 grams per daj parenterally are useful in the treatment of the above indicated conditions. Oral doses are 3-10 times higher. For example, renin- associated hypertension and hyperaldosteronism are effectively treated parenterally by the administration of from 1.0 to 50 milligrams of the compound per kilogram of body weight per day. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy. Thus, in accordance with the present invention there is further provided a pharmaceutical composition for treating hypertension and congestive heart failure, comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of the formula I. Also, in accordance with the present invention there is still further provided a method of treating hypertension and congestive heart failure, comprising administering to a patient in need of such treatment, a therapeutically effective amount of a compound of the formula I. The renin inhibitory compounds of the present invention may also be utilized in diagnostic methods for the purpose of establishing the significance of renin as a causative or contributory factor in hypertension or congestive heart failure in a particular patient. For this purpose the present compounds may be administered in a single dose of from 0.1 to 10 mg per kg of body weight. Both in vivo and in vitro methods may be employed. In the in vivo method, a novel peptide of the present invention is administered to a patient, preferably by intravenous injection, although other routes of parenteral administration are also suitable, at a hypotensive dosage level and as a single dose, and there may result a transitory fall in blood pressure. This fall in blood pressure, if it occurs, indicates supranormal plasma renin levels. Some of the compounds of formula I also have angiotensin converting enzyme (ACE) inhibitor activity. This activity augments renin inhibition in lowering blood pressure and in treating congestive heart failure. Treatment dosage and mode for this utility is generally the same as set out earlier. The preparation of the formula I compounds is illustrated in some of the examples below and in general proceeds as follows:
a) Coupling of an amino-protected form of E to G, followed by b) amino protecting group removal from E-G and c) coupling A to the resulting amino group of E-G. The phosphorous-containing component E, as well as the component A may contain functionality which requires protection during the coupling reactions. Protecting groups, among those well-known in peptide synthesis, are chosen so as to be compatible with the coupling steps, yet easily removable afterwards. Among those utilized for amino group protection are the t-butoxycarbonyl (BOC), benzyloxycarbonyl (CBZ), 9-fluorenylmethyloxycarbonyl ( FM OC), and benzyl groups. Carboxylic acids are protected as the methyl, ethyl, benzyl, or t-butyl esters. Phosphonic and phosphinic acids are protected as the methyl or ethyl esters. The coupling procedures referred to above include those brought about by use of dicyclohexylcarbodiimide/ 1-hydroxybenzotriazole and of disuccinimido oxallate (K. Takeda et al., Tetrahedron Lett., 24, 4451-54 (1983)). In many cases, both carboxylic and phosphonic (or phosphinic esters) may be hydrolyzed along with amino protecting groups as the last step in the synthesis. In these cases, treatment of the phosphorous-containing peptide analog with 30% hydrobromic acid in acetic acid, with 6N hydrochloric acid, or with aqueous sodium hydroxide, followed by purification of the resulting deprotected material by ion-exchange chromatography or reverse-phase HPLC, provides the desired product. In instances where A-E-G possesses a carboxyl-terminal amide function (R 3 =NH 2 , , or ), the fully coupled material A-E may be treated with 1 equivalent of lithium hydroxide (0.1 N) to hydrolyze selectively a carboxylic ester function in E. Standard coupling procedures may then be used to couple the resulting free carboxylic acid to an appropriate amine. This is followed by removal of the remaining protecting groups as described above. Alternatively the amide formation may be carried out prior to coupling of the component E-G to the A unit. Preparation of the phosphorous-containing components E are carried out as illustrated in the examples to follow. The 1-aminoalkylphosphonous acids used as starting materials in the examples below are prepared as illustrated in the examples and can be resolved to give optically active materials by the method of Baylis et al. (J. Chem. Soc. Perkin Trans 1, 2845-53 (1984)). Compounds derived from both the optically active and racemic materials are claimed in the present invention. The 1-aminoalkylphosphonic acids used in the examples below are prepared as described and can be resolved to give the optically active materials by the procedure of Kafarski et al., Can. J. Chem., 60, 3081-84 (1982), or can be prepared in optically active form by the method of Huber et al., Tetrahedron Lett., 3049-3052 (1979). Compounds derived from both the optically active and racemic materials are claimed in the present invention. When the amino group of the unit E which is to be coupled to A bears an N-methyl group (R6 = -CH 3 ), procedures well known in peptide synthesis are used to couple A to E or E-G. In general, the mixed anhydride procedure (with pivaloyl chloride and N-methylmorpholine) is used, as illustrated by R . M . Wenger, Helv. Chem. Acta., 1984, 67, 502-525. This procedure is also utilized in formation of E-G when G is
and R 8 is other than hydrogen and in the preparation of G when R9 is
and R 6 R 6 is methyl.

IPRDB

热门服务

关于我们

友情链接

联系方式